Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Clas Göran af Björkesten"'
Autor:
Tero Ylisaukko-oja, Clas-Göran af Björkesten, Anja Eberl, Heikki Nuutinen, Airi Jussila, Pauliina Molander, Ritva Koskela, Timo Blomster, Markku Pajala, Tuire Ilus, Paula Haiko, Bianca Kovac, Saija Silvola, Sarah Smith, Jari Jokelainen, Taina Sipponen
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e32432- (2024)
Purpose: To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting. Methods: Observational, retrospective, mu
Externí odkaz:
https://doaj.org/article/e518e647233a4961aed70816ba0f7dab
Autor:
Ritva Koskela, Clas-Göran af Björkesten, Jyrki Tillonen, Christian Nielsen, M Koivunen, Erkki Soini, Taru Hallinen, Ilkka Vihriälä, Airi Jussila, Ulla-Maija Suhonen, C Wennerström, Karri T Utriainen, Inka Koskinen, Kalle Hakala, R Nissinen, Tuire Ilus, Andras Borsi, Heikki Nuutinen, Markku Heikkinen, Veikko Moilanen, Taina Sipponen, Urpo Nieminen, Anja Eberl, Mikko Heikura
Publikováno v:
European Journal of Gastroenterology & Hepatology
Objective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn’s disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn
Autor:
Jyrki Tillonen, Ritva Koskela, M Koivunen, Ulla Maija Suhonen, Mikko Heikura, Christian Nielsen, Anja Eberl, Taru Hallinen, E Christina M Wennerström, Mikko Kellokumpu, Heikki Nuutinen, Markku Heikkinen, Erkki Soini, Tuire Ilus, Andras Borsi, Clas Göran af Björkesten, Taina Sipponen
Publikováno v:
Scandinavian journal of gastroenterology. 56(6)
Background: Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explore ustekinumab dosing dynamics and opti
Autor:
Taina Sipponen, Anja Eberl, Karri T Utriainen, Taru Hallinen, Ilkka Vihriälä, Jyrki Tillonen, Inka Koskinen, Andras Borsi, Christian Nielsen, Ulla-Maija Suhonen, Eija Hirsi, R Nissinen, C Wennerström, Heikki Nuutinen, M Koivunen, Mikko Kellokumpu, Clas-Göran af Björkesten, Erkki Soini, Markku Heikkinen, Veikko Moilanen
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn?s Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051170f4bddc4cdc187d73015a2d3579
http://hdl.handle.net/10138/306944
http://hdl.handle.net/10138/306944
Autor:
Ulla Turunen, Martti Färkkilä, Urpo Nieminen, Taina Sipponen, Clas-Göran af Björkesten, Perttu Arkkila
Publikováno v:
Scandinavian Journal of Gastroenterology. 47:528-537
Endoscopically confirmed mucosal healing has become an important therapeutic goal in the treatment of Crohn's disease (CD). The role of clinical indices, such as the Crohn's disease activity index (CDAI) and the Harvey-Bradshaw index (HBI), and surro
Autor:
Markku Saraheimo, Milla Rosengård-Bärlund, K. Pettersson-Fernholm, Marja-Riitta Taskinen, Lena M. Thorn, Clas Göran af Björkesten, Johan Wadén, Mats Rönnback, Merlin C. Thomas, J. Fagerudd, Per-Henrik Groop, Carol Forsblom
Publikováno v:
Diabetes Care. 28:2019-2024
OBJECTIVE—The aim of this study was to estimate the prevalence of the metabolic syndrome in Finnish type 1 diabetic patients and to assess whether it is associated with diabetic nephropathy or poor glycemic control. RESEARCH DESIGN AND METHODS—In
Autor:
Duvnjak, Marko, Virović-Jukić, Lucija, Gomerčić-Palčić, Marija, Stojsavljević, Sanja, Kocna, Petr, Neumaier, Michael, Kapitanović, Sanja, Čačev, Tamara, Vaníčková, Zdislava, Tomáš Zima, Treasure, Janet, Ertimiss Eshkevari, Cardi, Valentina, Krleža, Jasna Leniček, Bewick, Gavin, Radojković, Dragica, Zrinjka Mišak, Jadrešin, Oleg, Kuna, Andrea Tešija, Clas-Göran Af Björkesten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39dc32546e67cc5490cf2407269992e
Autor:
Clas-Göran af Björkesten, Johanna Haapamäki, Harri Mustonen, Taina Sipponen, Matti Vauhkonen, Martti Färkkilä, Kaija-Leena Kolho, Pauliina Molander
Publikováno v:
Inflammatory bowel diseases. 18(11)
Background: Fecal calprotectin (FC) concentration is a useful surrogate marker for mucosal healing (MH) during tumor necrosis factor alpha (TNFα)-blocking therapy for inflammatory bowel disease (IBD). Our aim was to evaluate whether a normal FC afte
Autor:
Clas-Göran af Björkesten, Urpo Nieminen, Martti Färkkilä, Ulla Turunen, Perttu Arkkila, Taina Sipponen
Publikováno v:
Inflammatory bowel diseases. 17(4)
Background: So far, infliximab (IFX) therapy for the treatment of Crohn's disease (CD) has generally been guided by clinical symptoms. Data on treatment response as ascertained by endoscopy in IFX therapy are scarce. The aims of this study were to me
Autor:
Erkki Savilahti, Taina Sipponen, Hannu Nuutinen, Clas-Göran af Björkesten, Kaija-Leena Kolho, Martti Färkkilä
Publikováno v:
Scandinavian journal of gastroenterology. 45(3)
Serial monitoring data for faecal calprotectin and lactoferrin during Crohn's disease (CD) therapy are scarce. The aim of this research was to study the behaviour of faecal biomarkers during CD therapy.Adult CD patients (n = 19) needing therapy enhan